Effect of Diabetes on Transscleral Delivery of Celecoxib

Overview

Journal Pharm Res

Specialties Pharmacology
Pharmacy

Date 2008 Nov 7

PMID 18987961

Citations 6

Authors

Narayan P S Cheruvu

Aniruddha C Amrite

Uday B Kompella

Affiliations

Soon will be listed here.

Abstract

Purpose: To investigate the effects of diabetes on transscleral retinal delivery of celecoxib in albino and pigmented rats.

Methods: Albino (Sprague Dawley-SD) and pigmented (Brown Norway-BN) rats were made diabetic by a single intraperitoneal injection of streptozotocin (60 mg/kg) following 24 h of fasting and diabetes was confirmed (blood glucose>250 mg/dL). Two months after diabetes induction, the integrity of blood-retinal-barrier in control versus diabetic rats from both strains was compared by using FITC-dextran leakage assay. Fifty microliter suspension of celecoxib (3 mg/rat) was injected periocularly in both the strains in one eye, 2 months following diabetes induction. The animals were euthanized at the end of 0.25, 0.5, 1, 2, 3, 4, 8, and 12 h post-dosing and celecoxib levels in ocular tissues and plasma were estimated using a HPLC assay.

Results: Diabetes (2-month duration) resulted in 2.4 and 3.5 fold higher blood-retinal barrier leakage in diabetic SD and BN rats, respectively, compared to controls. The area under tissue celecoxib concentration versus time curves (AUC) for sclera, cornea, and lens were not significantly different between control and diabetic animals. However, retinal and vitreal AUCs of celecoxib in treated eyes were approximately 1.5-fold and 2-fold higher in diabetic SD and BN rats, respectively, as compared to the controls.

Conclusions: Transscleral retinal and vitreal delivery of celecoxib is significantly higher in diabetic animals of both strains. The increase in retinal delivery of celecoxib due to diabetes is higher in pigmented rats compared to albino rats. Higher delivery of celecoxib in diabetic animals compared to control animals can be attributed to the disruption of blood-retinal barrier due to diabetes.

Citing Articles

Nanomedicines for back of the eye drug delivery, gene delivery, and imaging.

Kompella U, Amrite A, Pacha Ravi R, Durazo S Prog Retin Eye Res. 2013; 36:172-98.

PMID: 23603534 PMC: 3926814. DOI: 10.1016/j.preteyeres.2013.04.001.

RETRACTED: Influence of choroidal neovascularization and biodegradable polymeric particle size on transscleral sustained delivery of triamcinolone acetonide.

Kadam R, Tyagi P, Edelhauser H, Kompella U Int J Pharm. 2012; 434(1-2):140-7.

PMID: 22633904 PMC: 3573139. DOI: 10.1016/j.ijpharm.2012.05.025.

Pazopanib, a multitargeted tyrosine kinase inhibitor, reduces diabetic retinal vascular leukostasis and leakage.

Thakur A, Scheinman R, Rao V, Kompella U Microvasc Res. 2011; 82(3):346-50.

PMID: 21945644 PMC: 3233473. DOI: 10.1016/j.mvr.2011.09.001.

Recent advances in ophthalmic drug delivery.

Kompella U, Kadam R, Lee V Ther Deliv. 2011; 1(3):435-56.

PMID: 21399724 PMC: 3051398. DOI: 10.4155/TDE.10.40.

Ocular drug delivery.

Gaudana R, Krishna Ananthula H, Parenky A, Mitra A AAPS J. 2010; 12(3):348-60.

PMID: 20437123 PMC: 2895432. DOI: 10.1208/s12248-010-9183-3.

References

Tso M, Cunha-Vaz J, Shih C, Jones C . Clinicopathologic study of blood-retinal barrier in experimental diabetes mellitus. Arch Ophthalmol. 1980; 98(11):2032-40. DOI: 10.1001/archopht.1980.01020040884020. View

Ellis E, Guberski D, Hutson B, Grant M . Time course of NADH oxidase, inducible nitric oxide synthase and peroxynitrite in diabetic retinopathy in the BBZ/WOR rat. Nitric Oxide. 2002; 6(3):295-304. DOI: 10.1006/niox.2001.0419. View

Ghate D, Brooks W, McCarey B, Edelhauser H . Pharmacokinetics of intraocular drug delivery by periocular injections using ocular fluorophotometry. Invest Ophthalmol Vis Sci. 2007; 48(5):2230-7. DOI: 10.1167/iovs.06-0954. View

Ishibashi T, Tanaka K, Taniguchi Y . Disruption of blood-retinal barrier in experimental diabetic rats: an electron microscopic study. Exp Eye Res. 1980; 30(4):401-10. DOI: 10.1016/0014-4835(80)90055-x. View

Vinores S, Campochiaro P, McGehee R, Orman W, Hackett S, Hjelmeland L . Ultrastructural and immunocytochemical changes in retinal pigment epithelium, retinal glia, and fibroblasts in vitreous culture. Invest Ophthalmol Vis Sci. 1990; 31(12):2529-45. View

de Juan J, Moya F, Ripodas A, Bernal R, Fernandez-Cruz A, Fernandez-Durango R . Changes in the density and localisation of endothelin receptors in the early stages of rat diabetic retinopathy and the effect of insulin treatment. Diabetologia. 2000; 43(6):773-85. DOI: 10.1007/s001250051375. View

Tsui J, Dalgard C, Van Quill K, Lee L, Grossniklaus H, Edelhauser H . Subconjunctival topotecan in fibrin sealant in the treatment of transgenic murine retinoblastoma. Invest Ophthalmol Vis Sci. 2008; 49(2):490-6. DOI: 10.1167/iovs.07-0653. View

Blair N, Tso M, DODGE J . Pathologic studies of the blood--retinal barrier in the spontaneously diabetic BB rat. Invest Ophthalmol Vis Sci. 1984; 25(3):302-11. View

Ozturk F, Kurt E, Inan U, Kortunay S, Ilker S, Basci N . The effects of prolonged acute use and inflammation on the ocular penetration of topical ciprofloxacin. Int J Pharm. 2000; 204(1-2):97-100. DOI: 10.1016/s0378-5173(00)00483-x. View

10.

Cheruvu N, Amrite A, Kompella U . Effect of eye pigmentation on transscleral drug delivery. Invest Ophthalmol Vis Sci. 2008; 49(1):333-41. PMC: 3324932. DOI: 10.1167/iovs.07-0214. View

11.

Weijtens O, Feron E, Schoemaker R, Cohen A, Lentjes E, Romijn F . High concentration of dexamethasone in aqueous and vitreous after subconjunctival injection. Am J Ophthalmol. 1999; 128(2):192-7. DOI: 10.1016/s0002-9394(99)00129-4. View

12.

Ayalasomayajula S, Amrite A, Kompella U . Inhibition of cyclooxygenase-2, but not cyclooxygenase-1, reduces prostaglandin E2 secretion from diabetic rat retinas. Eur J Pharmacol. 2004; 498(1-3):275-8. DOI: 10.1016/j.ejphar.2004.07.046. View

13.

Ayalasomayajula S, Kompella U . Retinal delivery of celecoxib is several-fold higher following subconjunctival administration compared to systemic administration. Pharm Res. 2004; 21(10):1797-804. DOI: 10.1023/b:pham.0000045231.51924.e8. View

14.

Lee S, Geroski D, Prausnitz M, Edelhauser H . Drug delivery through the sclera: effects of thickness, hydration, and sustained release systems. Exp Eye Res. 2004; 78(3):599-607. DOI: 10.1016/s0014-4835(03)00211-2. View

15.

Ozturk F, Kortunay S, Kurt E, Inan U, Ilker S, Basci N . The effect of long-term use and inflammation on the ocular penetration of topical ofloxacin. Curr Eye Res. 1999; 19(6):461-4. DOI: 10.1076/ceyr.19.6.461.5277. View

16.

De Schaepdrijver L, Simoens P, LAUWERS H, De Geest J . Retinal vascular patterns in domestic animals. Res Vet Sci. 1989; 47(1):34-42. View

17.

Ozturk F, Kortunay S, Kurt E, Ubeyt Inan U, Ilker S, Basci N . Ofloxacin levels after intravitreal injection. Effects of trauma and inflammation. Ophthalmic Res. 1999; 31(6):446-51. DOI: 10.1159/000055570. View

18.

Amrite A, Edelhauser H, Kompella U . Modeling of corneal and retinal pharmacokinetics after periocular drug administration. Invest Ophthalmol Vis Sci. 2008; 49(1):320-32. PMC: 3324093. DOI: 10.1167/iovs.07-0593. View

19.

Dagher Z, Park Y, Asnaghi V, Hoehn T, Gerhardinger C, Lorenzi M . Studies of rat and human retinas predict a role for the polyol pathway in human diabetic retinopathy. Diabetes. 2004; 53(9):2404-11. DOI: 10.2337/diabetes.53.9.2404. View

20.

Vinores S, Campochiaro P, Lee A, McGehee R, Gadegbeku C, Green W . Localization of blood-retinal barrier breakdown in human pathologic specimens by immunohistochemical staining for albumin. Lab Invest. 1990; 62(6):742-50. View